Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Gastroenterology

Choose Topic

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA)

The Lancet: Gastroenterology & Hepatology | May 05, 2022

Intensive versus standard drug therapy for symptomatic Crohn's disease strictures (STRIDENT)

The Lancet: Gastroenterology & Hepatology | May 03, 2022

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST)

The Lancet: Gastroenterology & Hepatology | Apr 30, 2022

AJM300 (carotegrast methyl), an oral alpha4-integrin antagonist, for patients with moderate ulcerative colitis: a phase 3 trial

The Lancet: Gastroenterology & Hepatology | Apr 27, 2022

Dietary habits in patients with ulcerative colitis — a cause of nutrient deficiency?

Food and Nutrition Sciences | Apr 23, 2022

Statin use reduced hepatocellular carcinoma risk in patients with NAFLD

Clinical Gastroenterology and Hepatology | Feb 15, 2022 Preventive/Nutrition Preventive Medicine Clinical Pharmacology Hematology/Oncology Hepatobiliary/Pancreas Pharmacology/Therapy Gastroenterology Pharmacology/kinetics GI Oncology Hepatology

Guselkumab for the treatment of Crohn disease: Induction results from the phase 2 GALAXI-1 study

Gastroenterology | Feb 12, 2022 Inflammatory Bowel Dz Pharmacology/kinetics Small/Large Intestine Gastroenterology Clinical Pharmacology

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial

The Lancet: Gastroenterology & Hepatology | Feb 12, 2022 GI Oncology Pharmacology/Therapy Pharmacology/kinetics Pain Management/Palliative Care Hepatobiliary/Pancreas Hepatology

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomized, open-label, phase 2 trial

The Lancet: Gastroenterology & Hepatology | Feb 12, 2022 Pharmacology/kinetics Pharmacology/Therapy Hepatobiliary/Pancreas Hepatology

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

Diabetes, Obesity and Metabolism | Feb 12, 2022 Clinical Pharmacology Endocrinology Atherosclerosis/Lipids Diagnostics Diabetes Gastroenterology Radiology/Diagnostics Pharmacology/kinetics Hepatology

« Prev 1 2 3 4 5 … 553 Next »

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA)

Intensive versus standard drug therapy for symptomatic Crohn's disease strictures (STRIDENT)

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST)

AJM300 (carotegrast methyl), an oral alpha4-integrin antagonist, for patients with moderate ulcerative colitis: a phase 3 trial

Dietary habits in patients with ulcerative colitis — a cause of nutrient deficiency?

Statin use reduced hepatocellular carcinoma risk in patients with NAFLD

Guselkumab for the treatment of Crohn disease: Induction results from the phase 2 GALAXI-1 study

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomized, open-label, phase 2 trial

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Anaesthetic Management in Obese Patients

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA)

Intensive versus standard drug therapy for symptomatic Crohn's disease strictures (STRIDENT)

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST)

AJM300 (carotegrast methyl), an oral alpha4-integrin antagonist, for patients with moderate ulcerative colitis: a phase 3 trial

Dietary habits in patients with ulcerative colitis — a cause of nutrient deficiency?

Statin use reduced hepatocellular carcinoma risk in patients with NAFLD

Guselkumab for the treatment of Crohn disease: Induction results from the phase 2 GALAXI-1 study

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomized, open-label, phase 2 trial

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Anaesthetic Management in Obese Patients

Select Specialty

Select Topic